Abstract Body

Background

Dolutegravir (DTG) is not recommended for neonates due to absence of dosing guidelines and safety information. We are evaluating the multi-dose pharmacokinetics (PK) and safety of two pediatric DTG formulations in neonates: a dispersible scored tablet (DTG-DT, 10 mg) and a novel oral dispersible film (DTG-OF, 5 mg).

Methods

PETITE-DTG is an ongoing phase I/II, open-label, single center, two-stage trial in South Africa for term neonates exposed to HIV (N=56, birth weights ≥2kg). Stage 1 single dose DTG data (n=16) informed the multi-dose strategy for Stage 2: 5 mg DTG every 48 hours (q48) from Day 1 to 14 of life, followed by 5 mg daily (q24) until Day 28. In Stage 2, neonates born to mothers on DTG-based ART are randomized to receive either DTG-DT or DTG-OF with zidovudine postnatal prophylaxis. Three PK visits are performed: sparse on Day 1, intensive after ≥3 DTG doses, and sparse during week 4. Safety assessments are performed through week 6 of life. We report the interim PK/safety analysis after the first 20 neonates completed Stage 2. Target DTG criteria: geometric mean (GM) Ctau>0.67 µg/mL, and Cmax<17.0 µg/mL in the majority of neonates; proportion of neonates with Ctau <0.5 μg/mL (EC95) was also assessed.

Results

Ten neonates on DTG-DT and 10 on DTG-OF were included. Overall median (range) birth weight was 3.2 (2.6-4.1) kg and 1st DTG dose given at 48 (28-60) hours of life. Median age at PK sampling visits were 3, 7, and 23 days of life. DTG GM concentrations prior to the 1st dose (placenta washout) was 0.98 μg/mL. Intensive DTG PK profiles were similar between DTG-DT and DTG-OF, with both formulations achieving a DTG GM Ctau >0.67 µg/mL (Figure 1a). Two neonates, one on DTG-DT and one on DTG-ODF, had an Ctau <0.5 µg/mL, but both remained >0.22 µg/mL (>3-fold higher than DTG IC90 of 0.064 µg/mL). All neonates had a DTG Cmax<17.0 µg/mL across PK visits. Our prior neonatal DTG population PK model was updated with the multi-dose data and adequately predicted DTG concentrations (Figure 1b). No grade ≥3 adverse events (AEs) were related to DTG. Two grade 3 AEs unrelated to DTG were observed in one neonate with pneumonia. All neonates were HIV negative at study exit.

Conclusions

The multi-dose strategy of 5 mg DTG q48 from Day 1 to 14 of life, followed by 5 mg DTG q24 through day 28, was safe and achieved target concentrations for both DTG-DT and DTG-OF. This is the first evidence in neonates supporting the extension of DTG dosing recommendations from birth through week 4 of life.